Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from IM Cannabis Corp ( (IMCC) ) is now available.
IM Cannabis Corp., a Nasdaq-listed medical cannabis operator with integrated distribution, retail and online platforms in Israel and Germany, reported its audited results for the year ended December 31, 2025. The company continues to position itself as a data-driven medical cannabis provider while exploring expansion into additional technology-oriented sectors beyond cannabis.
For 2025, IM Cannabis posted revenue of C$54.7 million, with German sales jumping more than 134% to C$36.3 million and contributing over two-thirds of group revenue, driven by its EU-GMP-certified platform and Germany’s medical cannabis legalization. The company achieved a key milestone with positive operating cash flow of C$4.7 million, strengthened its cash and restricted cash to C$3.3 million through financings and debenture actions, and on March 17, 2026 signed a non-binding letter of intent to acquire 51% of Polish defense-tech firm Black Axe, signaling a strategic move into defense and homeland security technologies such as counter-drone and satellite intelligence solutions.
The most recent analyst rating on (IMCC) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on IM Cannabis Corp stock, see the IMCC Stock Forecast page.
Spark’s Take on IMCC Stock
According to Spark, TipRanks’ AI Analyst, IMCC is a Underperform.
The score is driven primarily by weak financial performance—ongoing losses, high leverage relative to equity, and continued cash burn. Technical signals also lean bearish with price below major moving averages and negative MACD, while valuation is difficult to support given a negative P/E and no dividend.
To see Spark’s full report on IMCC stock, click here.
More about IM Cannabis Corp
IM Cannabis Corp. is an international medical cannabis company operating in Israel and Germany, focused on building and scaling innovative businesses and technologies across global markets. It imports and distributes cannabis to medical patients, runs pharmacies and online platforms in Israel, and distributes medical cannabis to pharmacies in Germany through its subsidiary Adjupharm GmbH.
Average Trading Volume: 140,154
Technical Sentiment Signal: Sell
Current Market Cap: $2.14M
See more insights into IMCC stock on TipRanks’ Stock Analysis page.